Literature DB >> 17145042

The autocrine TNFalpha signalling loop in keratinocytes requires atypical PKC species and NF-kappaB activation but is independent of cholesterol-enriched membrane microdomains.

Steen Lisby1, Annesofie Faurschou, Robert Gniadecki.   

Abstract

Tumor necrosis factor alpha (TNFalpha) is involved in the pathogenesis of many inflammatory skin diseases. Epidermal keratinocytes produce and respond to TNFalpha via the cognate type 1 receptor (TNFR1). Little is known about regulation of TNFalpha signalling in this cell type. In this study, we report that in keratinocytes TNFalpha upregulates its own mRNA synthesis in an autocrine manner. This response peaks at approximately 1h of stimulation with TNFalpha but sustained elevated levels of TNFalpha mRNA are observed for up to 24h after stimulation and are dependent on the presence of the soluble cytokine. This autocrine response is mediated by the signalling cascade comprising TNFR1, atypical protein kinase C (aPKC) species and the transcription factor NF-kappaB, but is not dependent on the integrity of cholesterol-enriched membrane microdomains (lipid rafts). TNFalpha-stimulated keratinocytes produced the membrane-bound form of TNFalpha. It is conceivable that the described autocrine signalling loop contributes to the proinflammatory TNFalpha effect in the skin. The discovery of the crucial roles of aPKC and NF-kappaB might have consequences for the development of more selective anti-TNFalpha therapies for inflammatory skin diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145042     DOI: 10.1016/j.bcp.2006.11.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Inflammatory conditions distinctively alter immunological functions of Langerhans-like cells and dendritic cells in vitro.

Authors:  André Said; Stephanie Bock; Gerrit Müller; Günther Weindl
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

2.  UVB and proinflammatory cytokines synergistically activate TNF-alpha production in keratinocytes through enhanced gene transcription.

Authors:  Muhammad M Bashir; Meena R Sharma; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2008-11-13       Impact factor: 8.551

3.  Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.

Authors:  Olusegun Williams; Benjamin T Houseman; Eric J Kunkel; Brian Aizenstein; Randy Hoffman; Zachary A Knight; Kevan M Shokat
Journal:  Chem Biol       Date:  2010-02-26

4.  Pulmonary artery perfusion with anti-tumor necrosis factor alpha antibody reduces cardiopulmonary bypass-induced inflammatory lung injury in a rabbit model.

Authors:  Yang Yu; Mingxin Gao; Haitao Li; Fan Zhang; Chengxiong Gu
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

5.  Assessment of Anti-TNF-α Activities in Keratinocytes Expressing Inducible TNF- α: A Novel Tool for Anti-TNF-α Drug Screening.

Authors:  Sutthirat Udommethaporn; Tewin Tencomnao; Eileen M McGowan; Viroj Boonyaratanakornkit
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

Review 6.  Role of Ceramide from Glycosphingolipids and Its Metabolites in Immunological and Inflammatory Responses in Humans.

Authors:  Kazuhisa Iwabuchi; Hitoshi Nakayama; Ami Oizumi; Yasushi Suga; Hideoki Ogawa; Kenji Takamori
Journal:  Mediators Inflamm       Date:  2015-11-01       Impact factor: 4.711

7.  Pseudomonas-derived ceramidase induces production of inflammatory mediators from human keratinocytes via sphingosine-1-phosphate.

Authors:  Ami Oizumi; Hitoshi Nakayama; Nozomu Okino; Chihiro Iwahara; Katsunari Kina; Ryo Matsumoto; Hideoki Ogawa; Kenji Takamori; Makoto Ito; Yasushi Suga; Kazuhisa Iwabuchi
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

8.  Spontaneous NF-κB activation by autocrine TNFα signaling: a computational analysis.

Authors:  Jakub Pękalski; Pawel J Zuk; Marek Kochańczyk; Michael Junkin; Ryan Kellogg; Savaş Tay; Tomasz Lipniacki
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.